These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25763607)

  • 1. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant.
    Mancina RM; Matikainen N; Maglio C; Söderlund S; Lundbom N; Hakkarainen A; Rametta R; Mozzi E; Fargion S; Valenti L; Romeo S; Taskinen MR; Borén J
    J Clin Endocrinol Metab; 2015 May; 100(5):E821-5. PubMed ID: 25763607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Genetic Variant I148M in PNPLA3 Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans.
    Kovarova M; Königsrainer I; Königsrainer A; Machicao F; Häring HU; Schleicher E; Peter A
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1568-74. PubMed ID: 26439088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
    Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
    Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
    Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
    J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
    Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
    Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
    Hyysalo J; Gopalacharyulu P; Bian H; Hyötyläinen T; Leivonen M; Jaser N; Juuti A; Honka MJ; Nuutila P; Olkkonen VM; Oresic M; Yki-Järvinen H
    Diabetes; 2014 Jan; 63(1):312-22. PubMed ID: 24009255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
    Zampino R; Coppola N; Cirillo G; Boemio A; Pisaturo M; Marrone A; Macera M; Sagnelli E; Perrone L; Adinolfi LE; Miraglia del Giudice E
    J Viral Hepat; 2013 Aug; 20(8):517-23. PubMed ID: 23808989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.
    Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L
    Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
    Romeo S; Kozlitina J; Xing C; Pertsemlidis A; Cox D; Pennacchio LA; Boerwinkle E; Cohen JC; Hobbs HH
    Nat Genet; 2008 Dec; 40(12):1461-5. PubMed ID: 18820647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.